Market revenue in 2022 | USD 6,774.2 million |
Market revenue in 2030 | USD 5,554.7 million |
Growth rate | -2.5% (CAGR from 2022 to 2030) |
Largest segment | Hiv |
Fastest growing segment | Herpes |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | HIV, Hepatitis, Herpes, Influenza |
Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.35% in 2022. Horizon Databook has segmented the Germany antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has one of the strongest healthcare systems in Europe, which covers 90% of the population under mandatory health insurance coverage. This allows easy access to treatments, facilitating the adoption of antiviral drugs with an advanced infrastructure.
The presence of key market players in Germany and an increasing focus on geographic expansion as well as the launch of new products are among the factors driving the antiviral drugs market in Germany. The presence of research institutions and leading vaccine manufacturers are propelling the growth of Germany antiviral drugs market.
In addition, the surge in R&D activities and various strategic initiatives undertaken by leading participants are among the factors propelling market expansion. For instance, in October 2020, Atriva Therapeutics GmbH partnered with the European Investment Bank (EIB) with an investment of USD 25.93 million (EUR 24 million) for developing antiviral therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany antiviral drugs market , including forecasts for subscribers. This country databook contains high-level insights into Germany antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account